EA201390370A1 - MOLECULAR DIAGNOSTIC TEST FOR DETERMINATION OF ONCOLOGICAL DISEASE - Google Patents
MOLECULAR DIAGNOSTIC TEST FOR DETERMINATION OF ONCOLOGICAL DISEASEInfo
- Publication number
- EA201390370A1 EA201390370A1 EA201390370A EA201390370A EA201390370A1 EA 201390370 A1 EA201390370 A1 EA 201390370A1 EA 201390370 A EA201390370 A EA 201390370A EA 201390370 A EA201390370 A EA 201390370A EA 201390370 A1 EA201390370 A1 EA 201390370A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- therapeutic regimen
- test
- diagnostic test
- molecular diagnostic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Epidemiology (AREA)
- Data Mining & Analysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioethics (AREA)
- Artificial Intelligence (AREA)
- Software Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
Abstract
Предложены способы и композиции для идентификации молекулярно-диагностического теста на онкологическое заболевание. Тест определяет новый молекулярный подтип дефицита системы репарации повреждений ДНК и проводит классификацию пациента в пределах этого подтипа. Изобретение можно применять для определения того, способен ли пациент с онкологическим заболеванием дать клинический ответ на терапевтический режим или же он не способен дать клинический ответ на терапевтический режим, перед введением какой-либо химиотерапии. Данный тест можно применять при различных типах рака и в отношении различных лекарственных препаратов, которые напрямую или опосредованно воздействуют на повреждение или систему репарации ДНК, таких как многие стандартные цитотоксические химиотерапевтические лекарства, применяемые в настоящее время. В частности, изобретение относится к применению определенных комбинаций прогностических маркеров, при этом экспрессия прогностических маркеров коррелирует со способностью или неспособностью ответить на терапевтический режим.Methods and compositions are proposed for identifying a molecular diagnostic test for cancer. The test determines the new molecular subtype of the DNA damage repair system deficiency and classifies the patient within this subtype. The invention can be applied to determine whether a patient with cancer is able to give a clinical response to a therapeutic regimen or is incapable of providing a clinical response to a therapeutic regimen before administering any chemotherapy. This test can be used for various types of cancer and for various drugs that directly or indirectly affect the damage or DNA repair system, such as many of the standard cytotoxic chemotherapeutic drugs currently used. In particular, the invention relates to the use of certain combinations of prognostic markers, wherein the expression of prognostic markers correlates with the ability or inability to respond to a therapeutic regimen.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38320110P | 2010-09-15 | 2010-09-15 | |
US201161490039P | 2011-05-25 | 2011-05-25 | |
PCT/US2011/051803 WO2012037378A2 (en) | 2010-09-15 | 2011-09-15 | Molecular diagnostic test for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201390370A1 true EA201390370A1 (en) | 2013-07-30 |
Family
ID=45832248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201390370A EA201390370A1 (en) | 2010-09-15 | 2011-09-15 | MOLECULAR DIAGNOSTIC TEST FOR DETERMINATION OF ONCOLOGICAL DISEASE |
Country Status (16)
Country | Link |
---|---|
US (4) | US9670547B2 (en) |
EP (2) | EP2975399B1 (en) |
JP (2) | JP2013537045A (en) |
KR (1) | KR20130115250A (en) |
CN (2) | CN106978480A (en) |
AU (2) | AU2011302004B2 (en) |
BR (1) | BR112013006207A2 (en) |
CA (1) | CA2811015A1 (en) |
EA (1) | EA201390370A1 (en) |
HK (1) | HK1216665A1 (en) |
MX (1) | MX344636B (en) |
MY (1) | MY166040A (en) |
NZ (3) | NZ620799A (en) |
SG (2) | SG188397A1 (en) |
WO (1) | WO2012037378A2 (en) |
ZA (2) | ZA201301567B (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
JP2013537045A (en) | 2010-09-15 | 2013-09-30 | アルマック ダイアグノスティックス リミテッド | Molecular diagnostic tests for cancer |
CA2834535A1 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
CA2835179A1 (en) * | 2011-05-06 | 2012-11-15 | Xentech | Markers for cancer prognosis and therapy and methods of use |
AU2012261820B2 (en) | 2011-06-02 | 2017-01-19 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
WO2012178087A1 (en) * | 2011-06-22 | 2012-12-27 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of bladder cancer |
ES2872967T3 (en) * | 2012-06-29 | 2021-11-03 | Celgene Corp | Methods to determine drug efficacy using IKZF3 (AIOLOS) |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
BR112015005243A2 (en) * | 2012-09-10 | 2017-07-04 | Celgene Corp | Methods For Treating Locally Advanced Breast Cancer |
SG11201504023SA (en) * | 2012-12-03 | 2015-06-29 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
ES2761260T3 (en) | 2013-03-15 | 2020-05-19 | Hoffmann La Roche | Biomarkers and treatment procedures for conditions related to PD-1 and PD-L1 |
PL2984184T3 (en) * | 2013-04-09 | 2021-06-14 | The Board Of Trustees Of The University Of Illinois | Use of dnq or dnq-87 in combination with a parp1 inhibitor for the treatment of cancer |
GB201316027D0 (en) * | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for oesophageal cancer |
GB201316024D0 (en) * | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for lung cancer |
EP3052131B1 (en) | 2013-10-01 | 2018-12-05 | Mayo Foundation for Medical Education and Research | Methods for treating cancer in patients with elevated levels of bim |
CA2936077C (en) * | 2014-01-06 | 2020-06-30 | Expression Pathology, Inc. | Srm assay for pd-l1 |
GB201409479D0 (en) | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
WO2015168544A1 (en) * | 2014-05-02 | 2015-11-05 | Emory University | Selective chemotherapy treatments and diagnostic methods related thereto |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
EP3160486B1 (en) | 2014-06-27 | 2020-11-18 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
DK3309174T3 (en) | 2014-07-11 | 2022-06-07 | Ventana Med Syst Inc | ANTI-PD-L1 antibodies and diagnostic uses thereof |
WO2016014148A1 (en) | 2014-07-23 | 2016-01-28 | Mayo Foundation For Medical Education And Research | Targeting dna-pkcs and b7-h1 to treat cancer |
WO2016185406A1 (en) | 2015-05-19 | 2016-11-24 | Nadathur Estates Pvt. Ltd. | Method for identification of a deficient brca1 function |
GB201512869D0 (en) * | 2015-07-21 | 2015-09-02 | Almac Diagnostics Ltd | Gene signature for minute therapies |
WO2017013237A1 (en) * | 2015-07-23 | 2017-01-26 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
DE112016003948T5 (en) | 2015-08-31 | 2018-05-09 | City Of Sapporo | MOLECULAR METHODS FOR EVALUATING A UROTHIAL DISEASE |
CN108474040B (en) * | 2015-10-09 | 2023-05-16 | 夸登特健康公司 | Population-based treatment recommendations using cell-free DNA |
WO2017075045A2 (en) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US20170321285A1 (en) * | 2016-05-03 | 2017-11-09 | The Texas A&M University System | Nlrc5 as a biomarker for cancer patients and a target for cancer therapy |
WO2017216559A1 (en) * | 2016-06-14 | 2017-12-21 | Almac Diagnostics Limited | Predicting responsiveness to therapy in prostate cancer |
EP3535294A4 (en) | 2016-11-07 | 2020-09-30 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
CN108663519A (en) * | 2017-04-21 | 2018-10-16 | 江苏希摩生物科技有限公司 | Fast prediction and raising BRCA1/2 wild type ovarians cancer cell are to the method for Olaparib sensibility |
WO2018213141A1 (en) * | 2017-05-16 | 2018-11-22 | Hitachi Chemical Co. America, Ltd. | Methods for detecting ovarian cancer using extracellular vesicles for molecular analysis |
KR102574549B1 (en) * | 2017-06-27 | 2023-09-07 | 주식회사 뉴라클사이언스 | Anti-FAM19A5 Antibodies and Uses Thereof |
WO2019003162A1 (en) * | 2017-06-27 | 2019-01-03 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of glaucoma |
EP3645039A4 (en) * | 2017-06-27 | 2021-05-05 | Neuracle Science Co., Ltd | Use of anti-fam19a5 antibodies for treating fibrosis |
KR20220031738A (en) * | 2017-06-27 | 2022-03-11 | 주식회사 뉴라클사이언스 | Use of anti-fam19a5 antibodies for treating cancers |
CN110021357B (en) * | 2017-12-27 | 2021-06-04 | 浙江安诺优达生物科技有限公司 | Simulated cancer genome sequencing data generation device |
FR3078343A1 (en) | 2018-02-27 | 2019-08-30 | Lxrepair | METHOD FOR GENERATING A PROFILE OF REPAIR CAPABILITIES OF TUMOR CELL DNA AND ITS APPLICATIONS |
CN108379584B (en) * | 2018-04-12 | 2020-08-11 | 上海交复生物医药科技有限公司 | RSAD2 influences tumor cell temozolomide resistance through wnt pathway |
KR20240001331A (en) | 2018-04-24 | 2024-01-03 | 주식회사 뉴라클사이언스 | Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain |
CN108977547B (en) * | 2018-08-14 | 2019-05-28 | 江门市中心医院 | Application of the TSPAN1 in the diagnosis of Metastasis in Breast Cancer, prognosis and treatment |
CN109295208A (en) * | 2018-10-26 | 2019-02-01 | 德阳市人民医院 | Application of the PI15 as osteoarthritis marker |
CN109652540A (en) * | 2018-12-21 | 2019-04-19 | 思泰得精准(北京)医学检验实验室有限公司 | A kind of thyroid cancer early detection molecular marker and its application |
EP3902826A4 (en) * | 2018-12-27 | 2022-09-14 | Neuracle Science Co., Ltd | Use of anti-fam19a5 antibodies for treating atherosclerosis |
CA3143952A1 (en) * | 2019-02-22 | 2020-08-27 | Candel Therapeutics, Inc. | Gmci and ddri combination therapy for treating cancer |
CN110570922B (en) * | 2019-07-19 | 2022-06-10 | 浙江大学 | HR defect assessment model and application |
WO2021067310A1 (en) * | 2019-09-30 | 2021-04-08 | Candel Therapeutics, Inc. | Combination gmci and atri cancer treatment |
CA3227993A1 (en) * | 2021-08-11 | 2023-02-16 | OncoHost Ltd. | Predicting patient response |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
EP0636186B1 (en) | 1992-04-03 | 1998-11-25 | The Perkin-Elmer Corporation | Probe composition and method |
US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
JP2002515738A (en) | 1996-01-23 | 2002-05-28 | アフィメトリックス,インコーポレイティド | Nucleic acid analysis |
WO1997029212A1 (en) | 1996-02-08 | 1997-08-14 | Affymetrix, Inc. | Chip-based speciation and phenotypic characterization of microorganisms |
EP1002264B1 (en) | 1997-07-25 | 2004-04-14 | Affymetrix, Inc. (a Delaware Corporation) | Method for providing a bioinformatics database |
US7324926B2 (en) * | 1999-04-09 | 2008-01-29 | Whitehead Institute For Biomedical Research | Methods for predicting chemosensitivity or chemoresistance |
CA2514187A1 (en) | 2003-01-24 | 2004-08-12 | Bayer Pharmaceuticals Corporation | Expression profiles for colon cancer and methods of use |
KR20060013425A (en) | 2003-05-29 | 2006-02-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
US20090252721A1 (en) | 2003-09-18 | 2009-10-08 | Thomas Buschmann | Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer |
CN1905864B (en) * | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | DNA damage repair inhibitors for treatment of cancer |
JP5545690B2 (en) * | 2003-12-01 | 2014-07-09 | クドス ファーマシューティカルズ リミテッド | DNA damage repair inhibitors for cancer treatment |
US20050287544A1 (en) | 2003-12-01 | 2005-12-29 | Francois Bertucci | Gene expression profiling of colon cancer with DNA arrays |
EP2336779B1 (en) | 2004-02-19 | 2013-07-31 | Yale University | Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques |
US20060195266A1 (en) | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
WO2005083128A2 (en) | 2004-02-25 | 2005-09-09 | University Of South Florida | Methods for predicting cancer outcome and gene signatures for use therein |
NZ554895A (en) | 2004-11-03 | 2009-06-26 | Almac Diagnostics Ltd | Transcriptome microarray technology and methods of using the same |
US20070172844A1 (en) | 2005-09-28 | 2007-07-26 | University Of South Florida | Individualized cancer treatments |
EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
ES2491222T3 (en) | 2006-01-11 | 2014-09-05 | Genomic Health, Inc. | Gene expression markers for colorectal cancer prognosis |
WO2007084992A2 (en) * | 2006-01-19 | 2007-07-26 | The University Of Chicago | Prognosis and therapy predictive markers and methods of use |
US20070218512A1 (en) | 2006-02-28 | 2007-09-20 | Alex Strongin | Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management |
US20100009905A1 (en) | 2006-03-24 | 2010-01-14 | Macina Roberto A | Compositions and Methods for Detection, Prognosis and Treatment of Colon Cancer |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
EP2390360A1 (en) * | 2006-06-02 | 2011-11-30 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the IDO1 gene |
AU2007262635B2 (en) * | 2006-06-23 | 2014-09-11 | Adc Therapeutics Sa | Polynucleotides and polypeptide sequences involved in cancer |
WO2008005281A2 (en) * | 2006-06-30 | 2008-01-10 | Rosetta Inpharmatics Llc | Genes associated with chemotherapy response and uses thereof |
EP2092083A2 (en) * | 2006-10-20 | 2009-08-26 | Dana-Farber Cancer Institute | Dna damage repair inhibitors and methods for treating cancer |
US20100099720A1 (en) | 2007-01-18 | 2010-04-22 | Heinz-Josef Lenz | Gene Polymorphisms as Sex-Specific Predictors in Cancer Therapy |
EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
WO2008132176A2 (en) | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
US20120009581A1 (en) | 2008-07-08 | 2012-01-12 | Bankaitis-Davis Danute M | Gene Expression Profiling for Predicting the Survivability of Prostate Cancer Subjects |
WO2010040083A2 (en) | 2008-10-03 | 2010-04-08 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Gene expression predictors of chemoresistance |
US20110295782A1 (en) | 2008-10-15 | 2011-12-01 | Alexander Stojadinovic | Clinical Decision Model |
WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
WO2010060055A1 (en) | 2008-11-21 | 2010-05-27 | Duke University | Predicting cancer risk and treatment success |
WO2010118782A1 (en) * | 2009-04-17 | 2010-10-21 | Universite Libre De Bruxelles | Methods and tools for predicting the efficiency of anthracyclines in cancer |
US20120225789A1 (en) * | 2009-05-29 | 2012-09-06 | Baylor College Of Medicine | Dna repair or brca1-like gene signature |
WO2011153545A2 (en) | 2010-06-04 | 2011-12-08 | Bioarray Therapeutics, Inc. | Gene expression signature as a predictor of chemotherapeutic response in breast cancer |
JP2013537045A (en) | 2010-09-15 | 2013-09-30 | アルマック ダイアグノスティックス リミテッド | Molecular diagnostic tests for cancer |
-
2011
- 2011-09-15 JP JP2013529331A patent/JP2013537045A/en active Pending
- 2011-09-15 CN CN201710082290.2A patent/CN106978480A/en active Pending
- 2011-09-15 SG SG2013016175A patent/SG188397A1/en unknown
- 2011-09-15 KR KR1020137009145A patent/KR20130115250A/en not_active Application Discontinuation
- 2011-09-15 US US13/821,404 patent/US9670547B2/en active Active
- 2011-09-15 EP EP15181181.7A patent/EP2975399B1/en active Active
- 2011-09-15 SG SG10201610027VA patent/SG10201610027VA/en unknown
- 2011-09-15 CA CA2811015A patent/CA2811015A1/en not_active Abandoned
- 2011-09-15 EA EA201390370A patent/EA201390370A1/en unknown
- 2011-09-15 CN CN201180047116.5A patent/CN103299188B/en not_active Expired - Fee Related
- 2011-09-15 MX MX2013002879A patent/MX344636B/en active IP Right Grant
- 2011-09-15 NZ NZ620799A patent/NZ620799A/en not_active IP Right Cessation
- 2011-09-15 AU AU2011302004A patent/AU2011302004B2/en not_active Ceased
- 2011-09-15 MY MYPI2013000762A patent/MY166040A/en unknown
- 2011-09-15 WO PCT/US2011/051803 patent/WO2012037378A2/en active Application Filing
- 2011-09-15 NZ NZ608459A patent/NZ608459A/en not_active IP Right Cessation
- 2011-09-15 NZ NZ712823A patent/NZ712823A/en not_active IP Right Cessation
- 2011-09-15 EP EP11825959.7A patent/EP2619574B1/en active Active
- 2011-09-15 BR BR112013006207A patent/BR112013006207A2/en not_active Application Discontinuation
-
2013
- 2013-02-28 ZA ZA2013/01567A patent/ZA201301567B/en unknown
- 2013-10-07 US US14/047,949 patent/US9677140B2/en active Active
- 2013-12-23 HK HK16104700.5A patent/HK1216665A1/en unknown
-
2015
- 2015-08-13 US US14/825,480 patent/US10214777B2/en active Active
- 2015-11-26 ZA ZA2015/08689A patent/ZA201508689B/en unknown
-
2016
- 2016-01-28 AU AU2016200494A patent/AU2016200494B2/en not_active Ceased
- 2016-12-09 JP JP2016238969A patent/JP2017093440A/en active Pending
-
2017
- 2017-02-07 US US15/426,923 patent/US10378066B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201390370A1 (en) | MOLECULAR DIAGNOSTIC TEST FOR DETERMINATION OF ONCOLOGICAL DISEASE | |
MX2016003016A (en) | Molecular diagnostic test for lung cancer. | |
EA201391805A1 (en) | MOLECULAR DIAGNOSTIC CANCER TEST | |
MX2016003077A (en) | Molecular diagnostic test for oesophageal cancer. | |
MX2015006955A (en) | Molecular diagnostic test for cancer. | |
BRPI0906858B8 (en) | in vitro methods to detect the presence of a cancer cell in an individual and to identify a specific tumor signature in an individual having cancer. | |
BR112015012014A2 (en) | dual specific binding proteins penetrating the blood brain barrier (bbb) | |
PH12018550037A1 (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
NZ627443A (en) | Biological markers for identifying patients for treatment with vegf antagonists | |
MX2014016014A (en) | Methods for determining drug efficacy using cereblon-associated proteins. | |
WO2014036387A3 (en) | Methods for diagnosis and treatment of cancer | |
BR112015012644A2 (en) | method for determining a cancer patient's need, cancer treatment method, pharmaceutical composition, use of a nucleic acid or antibody and kit; | |
CY1114111T1 (en) | METHODS OF USE OF MIRNA TO DETECT IN VIVO CELL DEATH | |
WO2015031808A3 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
WO2011133668A3 (en) | Methods and compositions for the treatment of cancer | |
NZ612483A (en) | Drug selection for malignant cancer therapy using antibody-based arrays | |
BR112014018970A8 (en) | SAMPLE COLLECTION DEVICES WITH BLOOD STABILIZING AGENTS | |
SG10201906270VA (en) | Combination therapy comprising a b-raf inhibitor and a second inhibitor | |
BR112016007864A2 (en) | Method for cancer prognosis and metastasis treatment | |
BR112014027905A2 (en) | antibody, cell, nucleic acid, methods of identifying a first antibody, inhibiting cell growth, therapeutic treatment, determining the presence of a protein, diagnosing a tumor, and delivering a cytotoxic agent. | |
BR112017025254A2 (en) | Methods for detecting at least one mutation in a plurality of cancer-related genes, selecting an individual for treatment and predicting the likelihood of responsiveness to treatment. | |
TR201903026T4 (en) | S100A4 ANTIBODIES AND THEIR THERAPEUTIC USES. | |
WO2014026768A8 (en) | Colorectal cancer markers | |
BR112015022055A2 (en) | management of intravenous infusion care area transitions | |
BR112015008257A2 (en) | prdm14 and fam19a4 molecular diagnostic markers for hpv-induced invasive cancers and their high-grade precursor lesions |